OmniAb (OABI) Total Non-Current Liabilities (2021 - 2026)
OmniAb's (OABI) quarterly Total Non-Current Liabilities came in at $30.9 million in Q1 2026, down 5.06% year-on-year from $32.6 million in Q1 2025, and down 8.52% on a QoQ basis from $33.8 million in Q4 2025.
OmniAb (OABI) Total Non-Current Liabilities (2021 - 2026) Analysis & Trends
OmniAb (OABI) has 6 years of Total Non-Current Liabilities data on file, last reported at $30.9 million in Q1 2026.
- On a quarterly basis, Total Non-Current Liabilities fell 5.06% year-over-year to $30.9 million in Q1 2026; TTM through Mar 2026 was $30.9 million, a 5.06% decrease from a year earlier, with the FY2025 full-year figure at $33.8 million, down 10.69% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $30.9 million, down from $33.8 million in the prior quarter.
- Over the last five years, Total Non-Current Liabilities for OABI reached as high as $79.8 million in Q4 2022 and fell as low as $30.9 million in Q1 2026.
- Historically, Total Non-Current Liabilities has averaged $48.3 million across 5 years, with a median of $41.4 million in 2024.
- Across the five-year window, Total Non-Current Liabilities gained 22.13% in 2022 and plunged 37.5% in 2024, its largest moves.
- Year by year, Total Non-Current Liabilities stood at $79.8 million in 2022, then decreased by 28.02% to $57.4 million in 2023, then slumped by 34.09% to $37.9 million in 2024, then retreated by 10.69% to $33.8 million in 2025, then dropped by 8.52% to $30.9 million in 2026.
- Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $30.9 million in Q1 2026, $33.8 million in Q4 2025, and $32.2 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 4.45 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 110.28 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.98 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 949,738.67 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 5.87 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 7.32 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 40.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 746.94 Mn |
| 10 | OmniAb | 261.62 Mn | 212.55 Mn | 14.41 Mn | 30.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 30.93 Mn |
| Dec 31, 2025 | 33.81 Mn |
| Sep 30, 2025 | 32.17 Mn |
| Jun 30, 2025 | 33.53 Mn |
| Mar 31, 2025 | 32.58 Mn |
| Dec 31, 2024 | 37.85 Mn |
| Sep 30, 2024 | 39.77 Mn |
| Jun 30, 2024 | 43.03 Mn |
| Mar 31, 2024 | 51.13 Mn |
| Dec 31, 2023 | 57.44 Mn |
| Sep 30, 2023 | 63.64 Mn |
| Jun 30, 2023 | 68.05 Mn |
| Mar 31, 2023 | 72.20 Mn |
| Dec 31, 2022 | 79.79 Mn |
| Dec 31, 2021 | 65.33 Mn |